Search

Displaying results 3741 - 3750 of 10000 in total
  1. Drug

    Esmirtazapine

    go.drugbank.com/drugs/DB06678
    Investigational

    Merck has terminated its internal clinical development program for esmirtazapine as of March 2010.

  2. Drug

    AMG-553

    go.drugbank.com/drugs/DB18346
    Investigational

    AMG-553 is an adoptive, anti-FLT3 chimeric antigen receptor T-cell therapy generated through transduction of autologous T-cells with a self-inactivating human immunodeficiency virus-1 based lentiviral

  3. Drug

    Axicabtagene ciloleucel

    go.drugbank.com/drugs/DB13915
    ApprovedInvestigational

    It is marketed under the brand name Yescarta and is used to treat large B-cell lymphomas and follicular lymphoma in adults. … The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer.

    Synonyms: Autologous T cells transduced with retroviral vector encoding an anti-CD-19 CD28/CD3-zeta chimeric antigen receptorCategories: Complex Mixtures
  4. Drug

    KB002

    go.drugbank.com/drugs/DB05194
    Experimental

    KB002 is an engineered human IgG1k antibody engineered human. It is developed for the treatment of autoimmune diseases, initially rheumatoid arthritis.

  5. Drug

    Tragacanth

    go.drugbank.com/drugs/DB10667
    Approved

    Tragacanth allergenic extract is used in allergenic testing.

    Categories: Compounds used in a research, industrial, or household setting, Complex Mixtures
  6. Drug

    Rilzabrutinib

    go.drugbank.com/drugs/DB17709
    ApprovedInvestigational

    Rilzabrutinib is thought to work by dual mechanisms of action in ITP: It attenuates macrophage (Fcγ receptor)-mediated platelet destruction and reduces the production of pathogenic autoantibodies. … [L53743] ITP is an autoimmune disorder characterized by low platelet count.

    Synonyms: (e/z)-(r)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrile
  7. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [A245159,L40114] In approximately 90% of cases, patients develop immunoglobulin M (IgM) autoantibodies towards the I antigen on erythrocytes - these antibodies react optimally at 4°C and are therefore … [A245154] Notably, none of these agents are approved for use in the treatment of CAD.

  8. Drug

    Inotersen

    go.drugbank.com/drugs/DB14713
    ApprovedInvestigational

    It was FDA approved in October 2018. … Inotersen is a transthyretin-directed antisense oligonucleotide for the treatment of the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults.

  9. Drug

    MK-0354

    go.drugbank.com/drugs/DB05939
    Investigational

    MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. … It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.

  10. Drug

    LV-SMENP Vaccine

    go.drugbank.com/drugs/DB15804
    Experimental

    As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials. … is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which are based on